N-acetylcysteine infusion alters blood redox status but not time to fatigue during intense exercise in humans
- PMID: 12496140
- DOI: 10.1152/japplphysiol.00884.2002
N-acetylcysteine infusion alters blood redox status but not time to fatigue during intense exercise in humans
Abstract
Infusion of the antioxidant N-acetylcysteine (NAC) reduces fatigability in electrically evoked human muscle contraction, but due to reported adverse reactions, no studies have investigated NAC infusion effects during voluntary exercise in humans. We investigated whether a modified NAC-infusion protocol (125 mg. kg(-1). h(-1) for 15 min, then 25 mg. kg(-1). h(-1)) altered blood redox status and enhanced performance during intense, intermittent exercise. Eight untrained men participated in a counterbalanced, double-blind, crossover study in which they received NAC or saline (control) before and during cycling exercise, which comprised three 45-s bouts and a fourth bout that continued to fatigue, at 130% peak oxygen consumption. Arterialized venous blood was analyzed for glutathione status, hematology, and plasma electrolytes. NAC infusion induced no severe adverse reactions. Exercise decreased the reduced glutathione (P < 0.005) and increased oxidized glutathione concentrations (P < 0.005); NAC attenuated both effects (P < 0.05). NAC increased the rise in plasma K(+) concentration-to-work ratio (P < 0.05), indicating impaired K(+) regulation, although time to fatigue was unchanged (NAC 102 +/- 45 s; saline 107 +/- 53 s). Thus NAC infusion altered blood redox status during intense, intermittent exercise but did not attenuate fatigue.
Similar articles
-
Effects of intravenous N-acetylcysteine infusion on time to fatigue and potassium regulation during prolonged cycling exercise.J Appl Physiol (1985). 2004 Jan;96(1):211-7. doi: 10.1152/japplphysiol.00458.2003. Epub 2003 Sep 5. J Appl Physiol (1985). 2004. PMID: 12959960 Clinical Trial.
-
N-acetylcysteine enhances muscle cysteine and glutathione availability and attenuates fatigue during prolonged exercise in endurance-trained individuals.J Appl Physiol (1985). 2004 Oct;97(4):1477-85. doi: 10.1152/japplphysiol.00371.2004. Epub 2004 Jun 11. J Appl Physiol (1985). 2004. PMID: 15194675 Clinical Trial.
-
N-acetylcysteine attenuates the decline in muscle Na+,K+-pump activity and delays fatigue during prolonged exercise in humans.J Physiol. 2006 Oct 1;576(Pt 1):279-88. doi: 10.1113/jphysiol.2006.115352. Epub 2006 Jul 13. J Physiol. 2006. PMID: 16840514 Free PMC article. Clinical Trial.
-
Effects of training on potassium, calcium and hydrogen ion regulation in skeletal muscle and blood during exercise.Acta Physiol Scand. 1996 Mar;156(3):335-46. doi: 10.1046/j.1365-201X.1996.199000.x. Acta Physiol Scand. 1996. PMID: 8729694 Review.
-
N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency.Curr Opin Pharmacol. 2007 Aug;7(4):355-9. doi: 10.1016/j.coph.2007.04.005. Epub 2007 Jun 29. Curr Opin Pharmacol. 2007. PMID: 17602868 Free PMC article. Review.
Cited by
-
A single oral glucose load decreases arterial plasma [K+ ] during exercise and recovery.Physiol Rep. 2021 Jun;9(11):e14889. doi: 10.14814/phy2.14889. Physiol Rep. 2021. PMID: 34110701 Free PMC article. Clinical Trial.
-
Antioxidants and Skeletal Muscle Performance: "Common Knowledge" vs. Experimental Evidence.Front Physiol. 2012 Mar 12;3:46. doi: 10.3389/fphys.2012.00046. eCollection 2012. Front Physiol. 2012. PMID: 22416234 Free PMC article.
-
Cycling with blood flow restriction improves performance and muscle K+ regulation and alters the effect of anti-oxidant infusion in humans.J Physiol. 2019 May;597(9):2421-2444. doi: 10.1113/JP277657. Epub 2019 Mar 28. J Physiol. 2019. PMID: 30843602 Free PMC article.
-
Modulatory effect of N-acetylcysteine on pro-antioxidant status and haematological response in healthy men.J Physiol Biochem. 2010 Mar;66(1):15-21. doi: 10.1007/s13105-010-0002-1. Epub 2010 Mar 31. J Physiol Biochem. 2010. PMID: 20354834 Clinical Trial.
-
Delayed treatment with vitamin C and N-acetyl-L-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib.Int J Hematol. 2011 Jun;93(6):727-735. doi: 10.1007/s12185-011-0850-7. Epub 2011 Apr 28. Int J Hematol. 2011. PMID: 21526377
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical